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Background: This study investigated the effects of interleukin 23 (IL-23) on the production of cytokines
(IL-1, IL-4, IL-10, and IL-17), the differentiation of Treg/Th17 and STAT3 (i.e., signal transducer and acti-
vator of transcription 3) in human decidual immune cells (DICs) during early pregnancy.
Methods: DICs were treated with recombinant human IL-23 and an antibody against IL-23 subunit p19.
The differentiation of Treg and Th17 cells was detected by ﬂow cytometry. Levels of IL-23 receptor (IL-
23R), STAT3, and phosphorylated STAT3 (pSTAT3) was examined by Western blot. The production of IL1,
IL4, IL10, and IL-17 in DICs was measured by ELISA.
Results: Exogenous recombinant human IL-23 signiﬁcantly promoted the differentiation of Th17 cells
from DICs, while anti-IL-23 antibody signiﬁcantly promoted the differentiation of Treg cells from DICs.
Consistent with the differentiation of Th17 and Tregs cells, levels of IL-1b and IL-17 correlated positively
with IL-23 treatment, and anti-IL-23 antibody increased the secretion of IL-4 and IL-10 from DICs. Levels
of pSTAT3, but not STAT3 or IL-23R, were signiﬁcantly elevated by recombinant IL-23 treatment; anti-IL-
23 antibody signiﬁcantly decreased the levels of pSTAT3 and IL-23R in DICs.
Conclusions: IL-23 mediates the differentiation of Th17 and Treg cells and the production of associated
cytokines in DICs. The potential mechanism likely involves the STAT3 pathway.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interleukin 23 (IL-23) is a heterodimeric pro-inﬂammatory
cytokine comprising IL-12 subunit p40 and IL-23 subunit p19. IL-
23 is secreted by activated dendritic cells and macrophages [1],
and is a crucial member in the innate immune system. Moreover,
IL-23 facilitates the expansion and maintenance of T helper 17
(Th17) cellsdit can promote the differentiation of Th17 cells, and
within the Th17 cells, the production of IL-17 via IL-23R (IL-23 re-
ceptor) and STAT3 (signal transducer and activator of transcription
3) [2]. IL-17 is the dominant pro-inﬂammatory cytokine produced
by Th17 cells. It has pleiotropic effects such as inducing the release
of other cytokines that lead to proinﬂammatory processes and
neutrophil-mobilization [3]. IL-23 and IL-17 have been implicated
in the pathogenesis of many autoimmune diseases, such as in-
ﬂammatory bowel diseases, psoriatic arthritis, and spondyloar-
thritis [4e6].Cai), lmj20051699@126.com
Inc. This is an open access article uAn embryo may be considered as a semi-allograft to the mother,
andwill be rejected by themother's body if there is an imbalance in
immunological tolerance [7], similar to the mechanisms of patho-
genesis in autoimmune diseases. The decidua of the uterus is
importantly involved in alterations in the immune response during
key events such as blastocyst implantation, immunological toler-
ance, and trophoblast invasion, speciﬁcally through changes in
cytokine expression and leukocyte cell recruitment [8,9].
Unexplained recurrent miscarriage (URM) refers to 2 or more
pregnancy losses before the twentieth week of gestation [10]. The
precise causes of URM are largely unknown. Recent studies sug-
gested that IL-23 and IL-17 are involved in the pathogenesis of URM
[11,12]. It is well established that there is a balance between Th1/
Th2 and the regulatory T cell (Treg)/Th17 in the maternalefetal
interface, in which these cells secret cytokines including IL-1b, IL-4,
IL-10 and IL-17. These cytokines form a complex network that is
responsible for the maintenance of the pregnancy. An imbalance in
these cytokines may result in spontaneous abortion [13,14].
Many studies have reported that URM patients appear to have a
remarkably high amount of Th17 cells in the peripheral blood
[12,15] and decidua [16]. Decidual immune cells (DICs) are ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells in the maternalefetal interface [19]. However, the roles of IL-
23 in DICs have rarely been studied.
In the present study, to improve understanding of URM causes
we investigated effects of recombinant human IL-23 and IL-23
antibody on the production of cytokines (IL-1b, IL-4, IL-10 and IL-
17) and the level of STAT3 in DICs from early pregnancy.
2. Materials and methods
2.1. Human decidual tissue collection
The Ethics Committee of First Afﬁliated Hospital of Guangxi
Medical University (Nanning, China) approved this study. Each
participant provided written informed consent.
The decidual samples were collected from 15 healthy pregnant
women who sought an induced abortion at the Outpatient
Department of the Gynecology Clinic at First Afﬁliated Hospital of
Guangxi Medical University between January 2015 and May 2015.
The age of the patients was 27.05 ± 2.80 years and gestational age
was 51.80 ± 5.03 days. All pregnancies were determined intra-
uterine by ultrasound. None of the women were given treatment,
includingmisoprostol or mifepristone, before the induced abortion,
which was carried out by vacuum aspiration.
Decidual tissues from the aborted products were immediately
collected in a mixture of 50% Dulbecco's modiﬁed Eagle's medium
and 50% Ham's F-12 medium (DMEM/F12; Invitrogen, Life Tech-
nologies, Grand Island, NY) with antibiotics (100 IU/mL penicillin
and 100 mg/mL streptomycin) and washed in sterile phosphate-
buffered saline (PBS) before the isolation of DICs.
2.2. Isolation and culture of primary DICs
Isolation of DICs was performed as previously described [17].
Brieﬂy, decidual tissues were cut into 1-mm3 pieces and digested
with 2 mg/mL collagenase IV (Sigma, St. Louis, MO) and DNase I
(Sigma) at 37 C for 1 h. The cell suspensionwas successively passed
through 100, 300, and 400mesh screens and centrifuged at 600 g in
a discontinuous Percoll gradient. DICs that ranged in a density from
1.056 to 1.077 g/mL were recovered and cultured in 6-well plates in
DMEM/F12 supplemented with 10% fetal bovine serum (Gibco, Life
Technologies), 100 U/mL penicillin, and 100 mg/mL streptomycin
(complete medium) with 5% CO2 at 37 C. In consideration of the
phenotype alterations in different subjects, DICs from different
patients were not mixed.
2.3. Treatment of human ﬁrst-trimester DICs
DICs were seeded into 6-well plates (1.0  106/well) that were
pretreated with 10 mg/mL puriﬁed anti-CD3 antibody (functional
grade, eBioscience, San Diego, CA) overnight at 4 C. To examine the
effect of IL-23 on DIC cells, the wells with DICs were divided into 3
groups. The IL-23 group was treated with 3 ng/mL IL-23 protein
(Peprotech, Rocky Hill, NJ). The anti-IL-23 group received 0.4 mg/mL
anti-IL-23 antibody (eBioscience). The control group received no
treatment. Each treatment was performed in triplicate. Moreover,
to stimulate T lymphocyte differentiation in vitro, DICs of the 3
groups were cultured in the presence of 3 mg/mL anti-CD28 anti-
body (eBioscience) and 30 ng/mL IL-2 (Peprotech) in the culture
medium.
2.4. Flow cytometry
After treatment for 24 h, 2  106 DICs were collected, washed
with PBS and cultured in 1 mL of complete medium containingphorbol 12-myristate 13-acetate (PMA; 25 ng/mL) and ionomycin
(1 mg/mL) for 5 h. For labeling the Th17 cells, DICs were stained
using PerCP/Cy 5.5-conjugated anti-CD4 for 30 min at 4 C in the
dark, then washed with PBS and resuspended in Fix/Perm buffer
(BD Pharmingen, San Jose, CA, both) and incubated for 30 min at
4 C in the dark. After washing with Perm buffer twice, intracellular
staining was performed using phycoerythrin (PE) anti-human IL-17
(BD Pharmingen) for 30 min. For Treg analysis, DICs were stained
for PerCP-Cy5.5- conjugated anti-CD4, PE-conjugated anti-CD25,
and Alexa Fluor 647-conjugated anti-FoxP3 (BD). All stained cells
were acquired via a BD ﬂow cytometer with CellQuest software and
analyzed using Flowjo software (Treestar, Ashland, OR).
2.5. Enzyme-linked immunosorbent assay (ELISA)
After treatment for 12, 24 and 36 h, -the amount of culture
medium of the DICs were collected and centrifuged at 450  g for
5min. The supernatant was collected tomeasure the levels of IL-1b,
IL-2, IL-4, and IL-17 by ELISA in accordance with the manufacturer's
instructions (YUANYE, Shanghai, China). All samples were
measured in duplicate. The sensitivity of the ELISA kit was >1 pg/
mL for IL-1b and IL-4, and >0.1 pg/mL for IL-10 and IL-17.
2.6. Western blot
After treatment for 24 h, DICs werewashed in cold PBS and lysed
in RIPA lysis buffer (Beyotime, Shanghai, China) for 30 min at 4 C.
The cell lysate was collected by centrifugation at 12000  g for
20 min at 4 C. The protein concentration was determined by a
nucleic acid protein detector (ThermoScientiﬁc, Waltham, MA). A
total of 100 mg proteins were separated by 10% SDS-PAGE and
transferred onto a polyvinylidene ﬂuoride membrane (PVDF,
0.45 mm, Millipore, Billerica, MA). The membranes were blocked
using 0.5% bovine serum albumin for 2 h, and incubated with the
appropriate primary antibodies including STAT3 (1:2000, Cell
Signaling Technology, Danvers, MA); pSTAT3 (1:2000; Cell
Signaling Technology); IL-23R (1:500; Novus Biologicals, Littleton,
CO); IL-17R (1:1000; Novus Biologicals); and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 1:5000; Vazyme, Nanjing,
China), overnight at 4 C. After 2 washes, the membranes were
incubated with the appropriate ﬂuorescence-labelled secondary
antibody (1:10,000, Licor, Lincoln, NE) for 1 h. The protein bands
were detected using a Sweep membrane apparatus (LI-COR). The
levels of proteins were analyzed with Image J software (National
Institute of Health) and determined relative to GAPDH.
2.7. Statistical analysis
Data are presented as mean ± standard deviationStatistical
comparisons were performed using one-way analysis of variance
(ANOVA) or t-test with SPSS software (version 16.0; SPSS, Chicago,
IL). Comparisons between 2 sets of data were performed by post
hoc analysis. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Percentage of Th17 and Treg cells in DICs after treatment with
IL-23 and anti-IL-23 antibody
After treatment with IL-23 and anti-IL-23 antibody, the per-
centages of Th17 (CD4þIL-17Aþ) and Treg (CD4þCD25þFoxP3þ) T
cells in DICs were compared. The percentages of Th17/CD4þ in the
DICs of the control, IL-23, and anti-IL-23 groups were 1.31 ± 0.39%,
2.38 ± 0.73%, and 1.03 ± 0.27%, respectively (Fig. 1A). The per-
centages of Treg/CD4þ in the DICs of three groups were
Fig. 1. The differentiation of Treg and Th17 cells in decidual immune cells. (A) Cells stained with CD4 and IL-17 antibodies and analyzed by ﬂow cytometry. Th17 cells in DICs were
gated as CD4þIL-17þ T cells. (B) Cells stained with CD4, CD25, and FoxP3 antibodies and analyzed by ﬂow cytometry. Treg cells in DICs were gated as CD4þCD25þFoxP3þ T cells. The
statistical graph was made from 3 independent experiments.
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We found exogenous IL-23 protein signiﬁcantly increased the
percentage of Th17 cells (P < 0.05), while anti-IL-23 antibody
signiﬁcantly reduced the percentage of Th17 cells (P < 0.05, Fig. 1A).
Moreover, compared with the control, IL-23 treatment signiﬁcantly
decreased the percentage of Treg cells but anti-IL-23 antibody
signiﬁcantly increased the percentage of Treg cells (P < 0.05,
Fig. 1B). These results indicate that IL-23 can affect the differenti-
ation of Th17 and Treg cells in DICs.
3.2. Effect of IL-23 on the production of cytokines in DICs
To further address the roles of IL-23 in DICs, we carried out a
time-course study of the production of some cytokines (IL-1b, IL-4,
IL-10 and IL-17) in DICs after treatment with IL-23 and anti-IL-23
antibody. We found that recombinant human IL-23 signiﬁcantly
increased the production of IL-1b and IL-17 in DICs at 12 (not for IL-
1b), 24 and 36 h while anti-IL-23 antibody signiﬁcantly decreased
their production in DICs after 24 h (P < 0.05, Fig. 2). Compared with
the control group, the effect of recombinant human IL-23 on the
production of IL-4 and IL-10 in DICs was not signiﬁcant at all time
points (Fig. 2), but anti-IL-23 antibody signiﬁcantly increased the
production of IL-10 in DICs after 24 h (P < 0.05, Fig. 2). These data
suggest that IL-23 affects the production of cytokines in DICs. IL-23Fig. 2. Effect of IL-23 on the production of cytokines in DICs. DICs were cultured in t
cell culture medium was collected at 12, 24 and 36 h to measure the levels of IL-1b, IL-4, IL-1
※The difference is statistically signiﬁcant between the two groups.can stimulate the proinﬂammatory cytokines secretion such as IL-
1b and IL-17, and have a rising trend with the time.On the other
hand, anti-IL-23 can stimulate the anti-inﬂammatory cytokines
secretion such as IL-4 and IL-10 with the time, and inhibited the
production such as IL-1b and IL-17.
3.3. IL-23 regulates pSTAT3 expression in DICs
Since the initial step of IL-23 signaling is binding with its re-
ceptor, IL-23R, here we examined the effect of IL-23 and anti-IL-23
antibody on IL-23R expression in DICs. We observed that recom-
binant human IL-23 did not affect IL-23R expression but anti-IL-23
antibody signiﬁcantly inhibited IL-23R expression in DICs (P < 0.05,
Fig. 3A and B). Moreover, both recombinant human IL-23 and anti-
IL-23 antibody didn't change the expression of STAT3 in DICs
(P > 0.05), but the expression of pSTAT3 was signiﬁcantly elevated
by recombinant human IL-23 and inhibited by anti-IL-23 antibody
(P < 0.05, Fig. 3A and B). These data suggest that IL-23 regulates the
activation of STAT3 in DICs.
4. Discussion
IL-23 secreted by macrophages and dendritic cells induces the
differentiation of naive T cells into Th17 cells. It has beenhe presence of 3 ng/mL recombinant IL-23 or 0.4 mg/mL anti-IL-23 antibody, then
0 and IL-17 by ELISA. The statistical graph was made from 3 independent experiments.
Fig. 3. Effect of IL-23 on the expressions of IL-23R, STAT3 and p-STAT3 in DICs. (A) Representative images of each indicated protein achieved by Western blot. (B) The statistical
analysis of protein expression was conducted based on the densitometric intensity by image J software. GAPDH was used as an internal control and the expression of the target
protein was normalized to GAPDH.
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eases [6e8]. The IL-23 signaling pathway is likely to be an effective
therapeutic target for autoimmune diseases [4e6]. Since the em-
bryo is a semi-allograft to the mother, similar to autoimmune dis-
ease, the immune dysregulation at the maternalefetal interface
will cause pregnancy failure [7]. It has been reported that IL-23
expression in the human endometrium and decidua has certain
roles in pregnancy [18]. However, the present study is the ﬁrst to
describe the roles of exogenous IL-23 and anti-IL-23 antibody in
DICs from early pregnancy.
It is well established that the Th1/Th2 balance in circulating T
cells is dominated by Th2 during normal pregnancy, whereas Th1
dominance is associated with pregnancy failures such as URM [19].
Most studies have shown that the Th1/Th2 and Treg/Th17 ratios are
important to successful pregnancy, so they are regarded as thera-
peutic targets for treatment of URM [15,19,20]. Normal pregnancy is
characterized by Th2 and Treg dominance [21]. In this study, we
demonstrated that recombinant human IL-23 promoted the dif-
ferentiation of Th17 cells but inhibited the differentiation of Treg
cells. Conversely, anti-IL-23 antibody promoted the differentiation
of Treg cells but inhibited the differentiation of Th17 cells. These
data support that IL-23 expression in DICs is likely involved in the
regulation of the shift toward Treg and Th17.
A previous study reported that higher levels of pro-
inﬂammatory cytokines such as IL-1b and IL-17 were found in
URM patients compared with healthy pregnant women [22]. The
role of anti-IL-23 was found to inhibit inﬂammatory cytokines such
as IL-1b and IL-17. In the present study, we also found that the
production of IL-1b and IL-17 in DICs was signiﬁcantly inhibited by
anti-IL-23 antibody but increased by recombinant IL-23 protein. On
the contrary, the production of the Th2-type cytokine IL-4 was
signiﬁcantly increased by anti-IL-23 antibody but obviously
reduced by recombinant IL-23 protein. Moreover, previous evi-
dence indicated that IL-23 is responsible for the differentiation and
expansion of Th17 cells from naive CD4þT cells [23]. Our results are
consistent with previous ﬁndings that IL-23 contributes to the
differentiation of Th17 cells from DICs.
IL-10 is one of the cytokines secreted by Treg cells [27]. Here we
observed that the production of IL-10 in DICs was elevated by anti-
IL-23 antibody but slightly inhibited by IL-23 protein. This further
veriﬁes that anti-IL-23 antibody promotes the differentiation of
Treg cells from DICs. These results reveal that exogenous IL-23 or
anti-IL-23 antibody can change the immune microenvironment at
the maternalefetal interface, in which IL-23 promoted the pro-
duction of proinﬂammatory factors but anti-IL-23 antibody pro-
moted the secretion of inﬂammatory cytokine. These ﬁndings
provide evidence that IL-23 is a suitable therapeutic target for URM
treatment.
STAT3 is a key intracellular signaling protein. Its activation
(phosphorylation) is usually mediated by cytokines, growth factorreceptors, receptor-associated tyrosine kinases, and Janus kinase
(JAK)- and Src-associated kinases [24,25]. IL-23 receptors are
composed of the IL-23R subunit and the IL-12Rb1 subunit, which
are essential for the Th17 cell-mediated immune response [26]. IL-
23R is mostly expressed in memory and/or activated T cells but not
naive Th17 progenitor cells. Moreover, blocking IL-23R expression
using unique IL-23R antagonists can inhibit downstream IL-17
production and inﬂammation [27,28]. Here we found the anti-IL-
23 antibody could signiﬁcantly inhibit IL-23R expression, which is
consistent with reduced IL-17 production after anti-IL-23 antibody
treatment. It has been demonstrated previously that STAT3 is
involved in the IL-23R signaling pathway [29]. This study showed
that exogenous IL-23 could increase the expression of pSTAT3while
anti-IL-23 antibody signiﬁcantly inhibited the expression of
pSTAT3. These ﬁndings are consistent with the concept that IL-23
regulates the differentiation of Th17 cells from human peripheral
blood mononuclear cells through the IL-23/IL-23R/STAT3 pathway
[33]. However, this study is the ﬁrst report to elucidate the IL-23/
STAT3/IL-17 pathway in DICs from the maternalefetal interface.
In summary, we have demonstrated that IL-23 can promote the
differentiation of Th17 cells from DICs through the STAT3 pathway,
while anti-IL-23 antibody promotes the differentiation of Treg cells.
This study provides solid evidence for understanding the patho-
genesis of URM and considering IL-23 as a potential target for URM
treatment.
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